Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II, non-randomized, open-label, multi-center study to evaluate the efficacy
of neoadjuvant Sintilimab (PD-1 antibody) /+ chemotherapy as first-line treatment in patients
with stage III non-small cell lung cancer (NSCLC).